{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:36:02Z","timestamp":1791722162642,"version":"4.3.4"},"reference-count":14,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["TTU 09.822"],"award-info":[{"award-number":["TTU 09.822"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["09.914"],"award-info":[{"award-number":["09.914"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["16GW0229"],"award-info":[{"award-number":["16GW0229"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["16GW0227K"],"award-info":[{"award-number":["16GW0227K"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","award":["TTU 09.822"],"award-info":[{"award-number":["TTU 09.822"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","award":["09.914"],"award-info":[{"award-number":["09.914"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","award":["16GW0229"],"award-info":[{"award-number":["16GW0229"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","award":["16GW0227K"],"award-info":[{"award-number":["16GW0227K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Toxicological studies are a part of the drug development process and the preclinical stages, for which suitable vehicles ensuring easy and safe administration are crucial. However, poor aqueous solubility of drugs complicates vehicle screening for oral administration since non-aqueous solvents are often not tolerable. In the case of the anti-infective corallopyronin A, currently undergoing preclinical investigation for filarial nematode and bacterial infections, commonly used vehicles such as polyethylene glycol 200, aqueous solutions combined with cosolvents or solubilizers, or aqueous suspension have failed due to insufficient tolerability, solubility, or the generation of a non-homogeneous suspension. To this end, the aim of the study was to establish an alternative approach which offers suitable tolerability, dissolution, and ease of handling. Thus, a corallopyronin A-mesoporous silica formulation was successfully processed and tested in a seven-day toxicology study focused on Beagle dogs, including a toxicokinetic investigation on day one. Sufficient tolerability was confirmed by the vehicle control group. The vehicle enabled high-dose levels resulting in a low-, middle-, and high-dose of 150, 450, and 750 mg\/kg. Overall, it was possible to achieve high plasma concentrations and exposures, leading to a valuable outcome of the toxicology study and establishing mesoporous silica as a valuable contender for challenging drug candidates.<\/jats:p>","DOI":"10.3390\/pharmaceutics16030386","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T03:55:34Z","timestamp":1710215734000},"page":"386","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mesoporous Silica as an Alternative Vehicle to Overcome Solubility Limitations"],"prefix":"10.3390","volume":"16","author":[{"given":"Tim","family":"Becker","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Heitk\u00f6tter","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Krome","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"},{"name":"Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-2090","authenticated-orcid":false,"given":"Andrea","family":"Schiefer","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"},{"name":"Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-2465","authenticated-orcid":false,"given":"Kenneth","family":"Pfarr","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"},{"name":"Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-4034","authenticated-orcid":false,"given":"Alexandra","family":"Ehrens","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"},{"name":"Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-639X","authenticated-orcid":false,"given":"Miriam","family":"Grosse","sequence":"additional","affiliation":[{"name":"Department of Microbial Drugs, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 38124 Braunschweig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birthe","family":"Sandargo","sequence":"additional","affiliation":[{"name":"Department of Microbial Drugs, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 38124 Braunschweig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Stammberger","sequence":"additional","affiliation":[{"name":"Toxicological Consulting Services, 65795 Hattersheim am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-8671","authenticated-orcid":false,"given":"Marc","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Microbial Drugs, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 38124 Braunschweig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-418X","authenticated-orcid":false,"given":"Marc P.","family":"H\u00fcbner","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"},{"name":"Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kehraus","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"},{"name":"Institute of Pharmaceutical Biology, University of Bonn, 53115 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Hoerauf","sequence":"additional","affiliation":[{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"},{"name":"Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-7191","authenticated-orcid":false,"given":"Karl G.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0976-500X.81895","article-title":"Toxicological Screening","volume":"2","author":"Parasuraman","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/17425255.2.5.715","article-title":"Preclinical Formulations for Discovery and Toxicology: Physicochemical Challenges","volume":"2","author":"Neervannan","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_3","unstructured":"European Medicines Agency (2024, January 28). Guideline on Repeated Dose Toxicity, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-repeated-dose-toxicity-revision-1_en.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1091581815622442","article-title":"Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility","volume":"35","author":"Gad","year":"2016","journal-title":"Int. J. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1091581813485452","article-title":"Effects of Solutol (Kolliphor) and Cremophor in Polyethylene Glycol 400 Vehicle Formulations in Sprague-Dawley Rats and Beagle Dogs","volume":"32","author":"Stokes","year":"2013","journal-title":"Int. J. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/01926233221145112","article-title":"Pharmacobezoar Formation from HPMC-AS-Containing Spray-Dried Formulations in Nonclinical Safety Studies in Rats","volume":"50","author":"Gierke","year":"2022","journal-title":"Toxicol. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1039\/D2NP00012A","article-title":"Corallopyronin A: Antimicrobial Discovery to Preclinical Development","volume":"39","author":"Krome","year":"2022","journal-title":"Nat. Prod. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1517\/17425247.2016.1100165","article-title":"Mesoporous Silica Formulation Strategies for Drug Dissolution Enhancement: A Review","volume":"13","author":"McCarthy","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_9","unstructured":"GRACE (2024, February 24). Technical Data Sheet SYLOID\u00ae-XDP Silica-Solution for Liquisolid Formulations. Available online: https:\/\/grace.com\/products\/syloid-silica\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"119099","DOI":"10.1016\/j.ijpharm.2020.119099","article-title":"Mechanistic Aspects of Drug Loading in Liquisolid Systems with Hydrophilic Lipid-Based Mixtures","volume":"578","author":"Niederquell","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jps.23592","article-title":"Rational Development of Solid Dispersions via Hot-Melt Extrusion Using Screening, Material Characterization, and Numeric Simulation Tools","volume":"102","author":"Zecevic","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Krome, A.K., Becker, T., Kehraus, S., Schiefer, A., Steinebach, C., Aden, T., Frohberger, S.J., M\u00e1rmol, \u00c1.L., Kapote, D., and Jansen, R. (2020). Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A. Pharmaceutics, 21.","DOI":"10.3390\/pharmaceutics12111105"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Becker, T., Krome, A.K., Vahdati, S., Schiefer, A., Pfarr, K., Ehrens, A., Aden, T., Grosse, M., Jansen, R., and Alt, S. (2022). In Vitro\u2013In Vivo Relationship in Mini-Scale\u2014Enabling Formulations of Corallopyronin A. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081657"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcis.2021.06.089","article-title":"Polymer-Mediated Drug Supersaturation\u2014A Spotlight on the Interplay between Phase-Separated Amorphous Drug Colloids and Dissolved Molecules","volume":"603","author":"Hirlak","year":"2021","journal-title":"J. Colloid Interface Sci."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/3\/386\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:12:13Z","timestamp":1760105533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/3\/386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["pharmaceutics16030386"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16030386","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}